SCHEMBL3010161

SCHEMBL3010161

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)C1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.56
SMN1; SMN2 Q16637 10/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 9/20 0.45
NPC1 O15118 8/20 0.45
MAPK1 P28482 2/20 0.44
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ABL1 P00519 2/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 1/20 0.41
CRHBP P24387 1/20 0.41
MC4R P32245 1/20 0.41
CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012463 0.93 AR (0.47) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3005416 0.93 AR (0.47) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3013152 0.90 AR (0.54) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3012599 0.89 SMN1; SMN2 (0.54) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3021623 0.88 SMN1; SMN2 (0.47) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3014186 0.87 SMN1; SMN2 (0.47) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3015230 0.87 SMN1; SMN2 (0.58) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3018878 0.87 AR (0.55) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3007949 0.86 AR (0.60) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A
SCHEMBL3002120 0.86 AR (0.54) ARSMN1; SMN2L3MBTL1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.